PETVIVO HOLDING, INC. ANNOUNCES DISTRIBUTION AGREEMENT WITH NUPSALA LIMITED
PetVivo Holdings (OTCQX: PETV) has entered into a distribution agreement with Nupsala Limited to market and distribute Spryng® with OsteoCushion® technology throughout the United Kingdom, effective September 1, 2025.
Spryng® is an intra-articular injectable veterinary medical device containing sterilized, extra-cellular matrix microparticles that integrate with the animal's subsynovial tissue. The technology aims to restore proper joint mechanics and manage conditions like joint instability, degenerative joint disease, and osteoarthritis in horses, dogs, and cats.
PetVivo Holdings (OTCQX: PETV) ha stipulato un accordo di distribuzione con Nupsala Limited per commercializzare e distribuire Spryng® con tecnologia OsteoCushion® nel Regno Unito, con effetto dal 1 settembre 2025.
Spryng® è un dispositivo medico veterinario iniettabile intra-articolare contenente microparticelle di matrice extracellulare sterilizzate che si integrano con il tessuto subsinoviale dell'animale. La tecnologia è progettata per ripristinare la corretta meccanica articolare e gestire problemi come instabilità articolare, malattie degenerative dell'articolazione e osteoartrite in cavalli, cani e gatti.
PetVivo Holdings (OTCQX: PETV) ha firmado un acuerdo de distribución con Nupsala Limited para comercializar y distribuir Spryng® con tecnología OsteoCushion® en todo el Reino Unido, con vigencia desde el 1 de septiembre de 2025.
Spryng® es un dispositivo médico veterinario inyectable intraarticular que contiene micropartículas de matriz extracelular esterilizadas que se integran con el tejido subsinovial del animal. La tecnología busca restaurar la mecánica articular adecuada y tratar afecciones como la inestabilidad articular, las enfermedades articulares degenerativas y la osteoartritis en caballos, perros y gatos.
PetVivo Holdings(OTCQX: PETV)는 Nupsala Limited와 영국 전역에서 OsteoCushion® 기술을 적용한 Spryng®을 마케팅·유통하는 유통 계약을 체결했으며, 2025년 9월 1일부로 발효됩니다.
Spryng®은 멸균된 세포외기질 미세입자를 포함한 관절강내 주입형 수의학용 의료기기로, 동물의 활막하(subsynovial) 조직과 통합됩니다. 이 기술은 적절한 관절 역학을 회복하고 관절 불안정성, 퇴행성 관절 질환 및 골관절염과 같은 상태를 관리하도록 고안되었습니다(말, 개, 고양이 대상).
PetVivo Holdings (OTCQX: PETV) a conclu un accord de distribution avec Nupsala Limited pour commercialiser et distribuer Spryng® doté de la technologie OsteoCushion® dans tout le Royaume-Uni, à compter du 1er septembre 2025.
Spryng® est un dispositif médical vétérinaire injectable intra-articulaire contenant des microparticules de matrice extracellulaire stérilisées qui s'intègrent au tissu sous-synovial de l'animal. Cette technologie vise à restaurer la biomécanique articulaire et à gérer des affections telles que l'instabilité articulaire, les maladies articulaires dégénératives et l'arthrose chez les chevaux, chiens et chats.
PetVivo Holdings (OTCQX: PETV) hat eine Vertriebsvereinbarung mit Nupsala Limited geschlossen, um Spryng® mit OsteoCushion®-Technologie im gesamten Vereinigten Königreich zu vermarkten und zu vertreiben. Die Vereinbarung tritt am 1. September 2025 in Kraft.
Spryng® ist ein intraartikulär injizierbares veterinärmedizinisches Gerät, das sterilisierte Mikropartikel der extrazellulären Matrix enthält, welche sich mit dem subsynovialen Gewebe des Tieres verbinden. Die Technologie zielt darauf ab, die korrekte Gelenkmechanik wiederherzustellen und Erkrankungen wie Gelenkinstabilität, degenerative Gelenkerkrankungen und Arthrose bei Pferden, Hunden und Katzen zu behandeln.
- Expansion into the UK market through partnership with an established distributor
- Technology addresses multiple joint-related conditions in various animals
- Partnership enhances global market presence and accessibility of Spryng®
- None.
Insights
PetVivo's UK distribution deal with Nupsala expands global reach for its innovative joint therapy device, strengthening market position.
PetVivo's new distribution agreement with Nupsala Limited represents a strategic expansion of their commercial footprint into the United Kingdom market. This partnership enables PetVivo to leverage Nupsala's established distribution network and regional expertise to introduce their flagship product, Spryng® with OsteoCushion® Technology, to veterinary practitioners across the UK.
The agreement is particularly significant as it demonstrates PetVivo's execution of international growth strategies. By partnering with a respected UK distributor that specializes in musculoskeletal care for companion animals and horses, PetVivo gains immediate access to a sophisticated veterinary market without the substantial capital investment required to build their own distribution infrastructure.
Spryng® represents an innovative approach to treating joint conditions like osteoarthritis in animals through its extracellular matrix microparticles that integrate with synovial tissue. The product addresses a substantial market need, as degenerative joint disease affects millions of companion animals and performance horses, with limited effective treatment options currently available.
This type of strategic distribution partnership typically accelerates market penetration, as local distributors bring established relationships with veterinary practices. The commencement of sales activities on September 1, 2025, indicates a rapid implementation timeline, suggesting careful advance planning between the companies. For a small veterinary biomedical company like PetVivo, securing international distribution channels represents a critical milestone in scaling commercial operations and potentially driving revenue growth.
MINNEAPOLIS, Sept. 02, 2025 (GLOBE NEWSWIRE) -- PetVivo Animal Health, Inc., a wholly-owned subsidiary of PetVivo Holdings, Inc. (OTCQX: PETV; OTCID: PETVW) (collectively referred to herein as "PetVivo"), is an emerging biomedical device company focused on the commercialization of innovative medical devices and other therapeutics for equine and companion animals, announced today it has entered into a definitive distribution agreement with Nupsala Limited (“Nupsala”). Nupsala will inventory, market and promote PetVivo’s veterinary medical device, Spryng® with OsteoCushion® technology, throughout the United Kingdom. Nupsala’s sales and marketing activities will commence on September 1, 2025.
"We are pleased to announce this distribution agreement with Nupsala, which marks a significant step in expanding the global reach of Spryng® with OsteoCushion® Technology. Partnering with Nupsala, an experienced and respected distributor in the United Kingdom, allows us to bring this innovative solution to a broader population of veterinarians and animal owners. We are confident that, together, we will advance our mission of improving the quality of life for animals through cutting-edge technologies." stated Mike Eldred, Board Director for PetVivo Holdings, Inc.
SPRYNG® with OsteoCushion® Technology, is an intra-articular injectable veterinary medical device consisting of sterilized, extra-cellular matrix microparticles. The microparticles of Spryng® have been found to adsorb onto the joint synovial lining of animals and subsequently integrate with the animal’s subsynovial tissue. Such action promotes the restoration of proper joint mechanics, thereby aiding in the management of noninfectious sources of joint pain such as joint instability, degenerative joint disease and osteoarthritis.
"We are delighted to partner with PetVivo in bringing Spryng® to veterinarians and animal owners across the United Kingdom. At Nupsala, our focus has always been on advancing musculoskeletal care for horses, dogs, and cats through innovation, education, and trusted clinical partnerships. Spryng® compliments our mission by offering a novel, science-driven solution that supports joint function and enhances quality of life for animals affected by osteoarthritis and other degenerative conditions. We look forward to working alongside PetVivo to expand access to this important treatment and to provide veterinarians with the tools they need to deliver best-in-class care." Stated Greg McGarrell, Chief Executive Officer, Nupsala Group Ltd
About PetVivo Holdings, Inc.
PetVivo Holdings Inc. (OTCQX: PETV; OTCID: PETVW), in cooperation with PetVivo Animal Health, Inc., is an emerging biomedical device company currently focused on the manufacturing, commercialization and licensing of innovative medical devices and therapeutics for companion animals. The Company's strategy is to leverage human therapies for the treatment of companion animals in a capital and time efficient way. A key component of this strategy is the accelerated timeline to revenues for veterinary medical devices, which enter the market much earlier than more stringently regulated pharmaceuticals and biologics.
PetVivo has a robust pipeline of products for the treatment of animals and people. A portfolio of twenty-one patents protects the Company's biomaterials, products, production processes and methods of use. The Company’s lead products SPRYNG® with OsteoCushion® technology, a veterinarian-administered, intra-articular injection for the management of lameness and other joint related afflictions, including osteoarthritis, in cats, dogs and horses, and PrecisePRP™, a first-in-class, off-the-shelf, platelet-rich plasma (PRP) product designed for use by veterinarians, are currently available for commercial sale.
”For more information about PetVivo Holdings, Inc. please contact info1@petvivo.com or visit https://petvivo.com/, https://www.petvivoanimalhealth.com/ and https://www.sprynghealth.com.
CONTACT:
John Lai, CEO
PetVivo Holdings, Inc.
Email: info1@petvivo.com
(952) 405-6216
About Nupsala Limited
Nupsala Group Limited is a UK-based veterinary group specialising in musculoskeletal (MSK) health, orthobiologics, and regenerative medicine for companion animals and horses. The company operates as both a veterinary wholesaler and referral provider, offering a portfolio of trusted products and services that support the diagnosis and treatment of osteoarthritis and related MSK conditions. Through its integrated ecosystem—including clinical trials, synovial biomarker diagnostics, specialist MSK practices, and educational initiatives—Nupsala is committed to improving animal mobility, driving evidence-based practice, and partnering with veterinarians to deliver innovative, effective, and ethical solutions.
CONTACT:
Greg McGarrell, CEO
Nupsala Group, Ltd
Email: info@nupsala.com
+44 (0) 1865 922 227
Forward-Looking Statements:
The foregoing material may contain “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, each as amended. Forward-looking statements include all statements that do not relate solely to historical or current facts, including without limitation the Company’s proposed development and commercial timelines, and can be identified by the use of words such as “may,” “will,” “expect,” “project,” “estimate,” “anticipate,” “plan,” “believe,” “potential,” “should,” “continue” or the negative versions of those words or other comparable words. Forward-looking statements are not guarantees of future actions or performance. These forward-looking statements are based on information currently available to the Company and its current plans or expectations and are subject to a number of uncertainties and risks that could significantly affect current plans. Risks concerning the Company’s business are described in detail in the Company’s Annual Report on Form 10-K for the year ended March 31, 2024 and other periodic and current reports filed with the Securities and Exchange Commission. The Company is under no obligation to, and expressly disclaims any such obligation to, update or alter its forward-looking statements, whether as a result of new information, future events or otherwise.
FAQ
What is the new distribution agreement between PetVivo (PETV) and Nupsala Limited?
How does PetVivo's Spryng® technology work for animal joint treatment?
What conditions does PetVivo's Spryng® treatment target in animals?
When will Nupsala begin distributing PetVivo's Spryng® in the UK?
